Table 3.
Drugs | Synergistic | Additive | ND | |||
---|---|---|---|---|---|---|
no** | %* | no** | %* | no** | %* | |
AK\TDN | 22 | 88% | 3 | 12% | 0 | 0 |
CP\TDN | 20 | 80% | 3 | 12% | 2 | 8% |
CT\TDN | 24 | 96% | 1 | 4% | 0 | 0 |
CF\TDN | 25 | 100% | 0 | 0 | 0 | 0 |
Notes: *Percentages were correlated with number of MDR Pseudomonas aeruginosa isolates (N= 25); AK\TDN, combination of amikacin and titanium dioxide nanoparticles; no**, number of Pseudomonas aeruginosa isolates.
Abbreviations: MDR, multidrug-resistant; ND, not determined; CP, ciprofloxacin; CF, cefpime; CT, ceftriaxone; AK, amikacin; TDN, titanium dioxide nanoparticles; CP\TDN, combination of ciprofloxacin and titanium dioxide nanoparticles; CT\TDN, combination of ceftriaxone and titanium dioxide nanoparticles; CF\TDN, combination of cefpime and titanium dioxide nanoparticle.